Sustainable biosimilar policies in Europe

A review of approaches to biosimilar policy in Europe [1] highlights key principles for a sustainable biosimilar market, including supporting innovation and allowing for multiple suppliers.

US policy brief identifies barriers to biosimilars uptake

It was projected that by 2026, biosimilars could save up to US$150 billion in the specialty pharmaceuticals market. However, in the US, it has emerged that there are inherent barriers to market entry ...

EC approval for Sanofi’s insulin aspart biosimilar

The European Commission (EC) has issued marketing authorization for Sanofi’s insulin aspart biosimilar, which references Novo Nordisk’s product NovoLog and is used to treat type 1 and 2 diabetes.

Genentech and Amgen settle biosimilar disputes

Genentech has reached a settlement agreement with Amgen over its biosimilars of Herceptin (trastuzumab) and Avastin (bevacizumab). All claims have been dismissed, allowing Amgen to continue marketing ...

Biosimilar infliximab uptake in Canada

The first biosimilar infliximab was sold in Canada in 2015, yet by 2018 uptake was still less then 10%, data from the Patented Medicine Prices Review Board (PMPRB) reveal.